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Summary Bcl-2 expression in colorectal carcinomas was studied in a series of 224 patients and the relation to p53 expression, stage and
survival assessed. Bcl-2 expression wasdown-regulated compared with normal mucosa in 67% (151) ofthe cases. In 144 cases staining was
positive for p53 (MAB D07), and 41 of these 144 p53-positive cases were also bcl-2 positive (28%) comeared with 32 of the remaining 80
p53-negative cases (40%). Survival was significantly worse (P= 0.01) in the p53-positive cases. Bcl-2-positive cases, including patients in all
Dukes' stages, had a slightly better prognosis which was not statistically significant. However, cases at an early stage (Dukes' stages A and
B) and with negative p53 status, had a much better prognosis if they showed bcl-2 protein expression, suggesting that the bcl-2 status itself
has an effect on prognosis (P= 0.01). Neither bcl-2 nor p53 alone was correlated with stage, but when examined by both p53 and bcl-2 status
a group [bcl-2(+)/p53(-)] with better prognosis was defined. The last group was significantly lower Dukes' stage, with 26 out of 32 cases
(81%) being A or B compared with 22 (11%) of the 202 remaining cases (P =0.004). Thus, either loss of bcl-2 expression orgain of abnormal
p53 expression is associated with high stage and poor prognosis. The bcl-2(+)/p53(-) phenotype is similar to that of normal mucosa, and
these results suggest that such cases represent an indolent group at an early stage in the progression of colorectal cancer.
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The bcl-2 gene was originally described as an oncogene associated
with the 14:18 translocation, which is often present in follicular
lymphomas (70%) and also in a minority ofdiffuse lymphomas of
B-cell type (20%) (Fukuhara et al, 1979; Tsujimoto et al, 1984;
Cleary and Sclar, 1985). This translocation produces abnormally
high levels ofotherwise normal bcl-2 protein, and its detection by
immunocytochemistry was initially thought to be a specific
marker for neoplastic lesions bearing this chromosomal abnor-
mality. It was also thought that this protein product was not
detectable in normal tissues, either within or outside the lymphoid
system (Bakhshi et al, 1985; Cleary et al, 1986; Tsujimoto and
Croce, 1986; Tsujimoto et al, 1987; Ngan et al, 1988).
Further studies, however, proved that this is not the case and
that bcl-2 protein is expressed in a variety of normal tissues and
in neoplastic tissues which are not necessarily lymphoid and
in which no chromosomal translocation was demonstrated
(Hockenberry et al, 1991).
The physiological role of bcl-2 is different from that of other
oncogenes and is not related to inducation ofcellular proliferation
or neoplastic transformation (Vaux et al, 1988). Its expression
allows cells to prolong survival even without the presence of
growth factors, because it inhibits programmed cell death
(apoptosis) (Hockenberry et al, 1990, 1993).
Using suitable antibodies, the bcl-2 protein was detected not only
in lymphoid cells but also in neurons and in a variety of epithelial
tissues, including skin, intestine, lung, breastandprostate (Lebrunet
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al, 1993; Lu et al, 1993). Its pattern of expression is different in
different tissues. It is detectable inbasal cells but not in the differen-
tiated, more superficial ones (skin, intestine, lung), whereas inbreast
it is the luminal cells which are positive. It appears, therefore, that
bcl-2 may be regulated differently and may have different roles in
each ofthe cell types or tissues expressed. This observation is very
important when tumours originating from these cells are studied
(Hockenberry et al, 1991).
Although bcl-2 was the first mammalian gene discovered to be
involved in the regulation ofcell death, other genes includingp53
orproteins that can heterodimerize with bcl-2 such as bax, bcl-XL,
bcl-Xs are also implicated in the control of apoptosis (Boise et al,
1993; Oltvai et al, 1993). In particular, p53 induces apoptosis in its
wild-type form, an action antagonized by bcl-2, whereas mutant
p53 proteins may make cells resistant to programmed cell death
(Shaw et al, 1992; Wang et al, 1993).
Studies of bcl-2 expression in solid tumours have shown a rela-
tion to good prognosis in non-small-cell lung cancer (Pezzella et al,
1993) andassociation with goodprognostic features in breast cancer
(Leek et al, 1994). In neuroblastomas, bcl-2 expression, not supris-
ingly, was associated with high stage and unfavourable histology,
reflecting its restricted expression in less differentiated cells (Castle
etal, 1993). In arecentstudy intissues with arapidturnover, such as
colorectal mucosa, bcl-2 was found only in the crypt cells of the
colonic pits and was not present in hyperplastic polyps. In the
neoplastic counterpart, bcl-2 was detected in the majority of
adenomas (85%) but in only 25-30% of the invasive carcinomas,
reflecting a possible down-regulation (Kaklamanis et al, 1996).
In this study, we examined a large series of patients (224) with
colorectal carcinomas for whom detailed information on follow-up
was available, intending toestablish whetherornotbcl-2 expression
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Table 1 Clinicopathological features in relation to bcl-2 and p53 expression
Clinicopathological Colorectal carcinomas
features
bcl-2 (+) bcl-2 (-) p53 (+) p53 (-)
Number of patients 73 151 144 80
Sex (M/F) 44/29 81/70 79/65 46/34
Range of age at 43-89 37-87 37-87 43-89
operation (median) (68.3) (67.1) (66.9) (67.8)
Dukes; stage
A 11 17 16 12
B 35 59 57 37
C 27 75 71 31
Differentiation
Good 18 32 38 12
Moderate 48 107 95 60
Poor 7 12 11 8
Site (219 cases)
Colon 41 89 77 53
Rectum 30 59 62 27
Table 2 Clinicopathological parameters in relation to combined bcl-2/p53
status
Clinicopathological Colorectal carcinomas
features
bcl-2 (+)l bcl-2 (-)I bcl-2 (+) bcl-2 (-)I
p53 (-) p53 (-) p53 (+) p53 (+)
Number of patients 32 48 41 103
Sex (M/F) 22/10 24/24 22/19 57/46
Range of age at 43-89 43-82 43-84 37-87
operation (median) (68.1) (67.4) (68.5) (65.4)
Dukes' stage
A 6 6 5 11
B 20 17 15 42
C 6 25 21 50
X2 = 10.7 P< 0.01
Lymph node status
Negative 26 23 20 53
Positive 6 25 21 50
X2 = 8.3 P< 0.004
Differentiation
Good 7 5 11 27
Moderate 22 38 26 69
Poor 3 5 4 7
Site (219 cases)
Colon 20 33 21 58
Rectum 12 15 20 45
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Figure 1 Survival of patients with colorectal carcinoma according to status
for bcl-2 protein expression (A) and p53 overexpression (B)
for colorectal carcinoma at the John Radcliffe Hospital, Oxford,
between 1988 and 1994. Sections of non-neoplastic colonic
mucosa were also examined. Histological diagnosis, assessment of
differentiation and staging were done by light microscopy.
Antibodies
The primary antibodies used were for bcl-2, the bcl-2/124 mono-
clonal antibody (Dako) and, for p53, two p53 monoclonal anti-
bodies (D07-Dako and 240).
is related to prognosis. The same cases were also analysed with a
panel ofmonoclonal antibodies forthe p53 tumour-suppressor gene
as it is involved both in colorectal tumorigenesis and in apoptotic
pathways.
MATERIALS AND METHODS
Tissue samples
Samples were taken from both frozen and paraffin-embedded
material obtained from 234 patients who had undergone resection
Validation study
Sections from 30 paraffin-embedded tissues and frozen tissues
from the same patients were analysed with bcl-2 and p53 anti-
bodies. The immunoreactivity of bcl-2/124 antibody is almost
identical on both types of tissues. The p53 (240) antibody was
positive in more cases using frozen sections (- 65%) than on
paraffin ones (- 40%), while D07 showed similar staining
patterns on both paraffin and frozen sections (- 65%). For this
reason the results obtained with the bcl-2/124 and p53/DO7 anti-
bodies in the following statistical analysis are used.
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Figure 2 Survival of patients with colorectal carcinoma according to status
for bcl-2/p53 subgroups
A bcl-2
Methods
Paraffin sections (4gm thick) were mounted on silane-coated
slides, dewaxed in Citroclear and rehydrated in graded alcohols.
The slides were incubated twice for 4 min at 700 W in a Proline
Powerwave 800 microwave oven and then placed in covered glass
jars filled with citrate buffer. After microwaving, the slides were
allowed to cool down at room temperature (20-30 min), washed
with buffered saline and immunostained with the three-stage
immunoperoxidase method.
Patients
All patients were classified according to Dukes' classification (A,
B and C stages). Patients who died within the first month or from
other causes not related to their disease were excluded from
survival analysis. Follow-up of 224 patients included in the
B p53
E
Figure 3 (A and B) An invasive carcinoma showing cytoplasmic staining for bcl-2 and nuclear staining for p53 respectively; (C and D) a case showing bcl-2
expression and no labelling for p53; (E and F) a carcinoma negative for bcl-2 (note the positive mantle zone around the follicular centre and positive for p53
expression
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analysis ranged from 1 month to 72.5 months with a median of36
months. At the time the study was performed 59 patients had died
from their disease.
Table 1 shows the clinicopathological characteristics of all 224
patients in whom bcl-2 and p53 expression were analysed sepa-
rately, and Table 2 shows those in whom survival was studied
according to their combined bcI-2/p53 status.
Statistical analysis
Survival curves were plotted using the method of Kaplan and
Meier and a log-rank test was used to determine statistical differ-
ences between life tables. A Cox proportional hazard model was
used to assess the effect of patient and tumour variables on
survival. A chi-squared test was used for testing relationships
between categorical variables, and a t-test was used for testing
differences between means of continous variables. The statistical
analysis was performed using the Stata 3.1 Package (Stata
Corporation, TX, USA).
RESULTS
bcl-2 protein expression
From the 224 patients studied, 73 (33%) tumours showed positive
cytoplasmic labelling with the bcl-2 antibodies. Cases were
regarded as positive iflabelling was detected in more than 10% of
the cell population. The non-neoplastic colorectal mucosa adjacent
to the tumour showed immunoreactivity only at the cells of the
crypts, whereas the overlying, more differentiated superficial and
luminal cells were negative.
p53 immunostaining
Over expression of p53 was found in 144 cases (64%). The
staining was nuclear and heterogeneous. Cases were regarded as
positive if more than 25% of the neoplastic cells within a tumour
were labelled. Non-neoplastic colorectal mucosa, lymphocytes
and stromal cells did not show any immunoreactivity. Although
detection of p53 overexpression by immunocytochemical means
does not necessarily imply a mutant form of the gene, in most
(85%) of the cases p53 overexpression coincides with an under-
lying mutation (Bass et al, 1994).
Clinicopathological features and bcl-2/p53 expression
The median age of the 224 patients was 67 years and the median
size ofthe tumour 5.4 cm (range 1-20 cm). In total, 28 cases were
Dukes' stage A (12%), 94 Dukes' B (42%) and 102 Dukes' C
(45%). The tumour was well differentiated in 50 cases (22%),
moderately differentiated in 155 (69%) and poorly differentiated
in 19 (9%) cases. Eighty-nine carcinomas (41%) arose from the
rectal mucosa and 130 (59%) from the colon.
There was no significant correlation between the bcl-2 status
and stage, differentiation, age, sex or location of the tumour. The
same was true when the p53 only status was correlated with these
clinicopathological parameters.
However, stratifying patients by both bcl-2 and p53 status, it was
observed that cases which show the bcl-2(+)/p53(-) phenotype are
usually within the Dukes' A and B stages, in other words they are
lymph node (LN) negative tumours [only 6 of the 32 cases (19%)
showed positive LN status]. Comparing this phenotype, which is
similar to that of normal mucosa, with all the other cases shows a
highly significant difference for stage (%2 = 10.7, P < 0.01).
When lymph node status alone was compared in this group
and other groups, especially those with the bcl-2(-)/p53(+)
immunophenotype [50 out of 103 cases (50%) showed metastasis
to the regional lymph nodes], there was also a significant differ-
ence (X2 = 8.3, P < 0.004, Table 2).
Survival and bcl-2/p53 expression
There was no significant difference in survival between patients
withbcl-2-positive tumours andthose withbcl-2-negative, but bcl-
2-positive patients did slightly better (%2 = 2.58, P = 0.1).
However, among the Dukes' A and B cases with p53-negative
status, there were 26 bcl-2-positive patients (and all ofthem alive)
and 23 bcl-2-negative patients (among whom five deaths were
recorded), implying that bcl-2 status itself has an effect on prog-
nosis (P = 0.01).
Stratifying patients by p53 status showed a significant differ-
ence in survival (%2 = 6.12, P = 0.01), with p53-positive patients
having a worse prognosis (Figure IA and B). A Cox proportional
hazard model showed ahazard ratio of 1.21 with a95% confidence
interval (CI) of 0.61-2.38 for bcl-2 status, and a hazard ratio of
1.19 with 95% CI of0.58-2.44 for p53 status.
An inverse relationship was observed between p53 and bcl-2
[32/80 for bcl-2(+)/p53(-) compared with 41/144 for bcl-
2(-)/p53(+)], but this did not reach statistical significance (%2 =
2.1, P = 0.14). Stratifying by both bcl-2 andp53 status, there was a
significant difference in survival (x2 = 9.41, P = 0.02) between the
four subgroups. Patients with p53-positive status did worse than
p53-negative patients and, within those groups, patients with bcl-
2-negative status had a poorerprognosis (Figure 2).
The group of patients with the bcl-2(+)/p53(-) phenotype
showed a much better prognosis than all the other groups together
(x2 = 6.60, P = 0.01), whereas the bcl-2(-)/p53(+) group did much
worse than the other groups (x2 = 5.29, P = 0.02). If these two
groups are compared with each other, there is a significant differ-
ence in survival (x2 = 8.32, P = 0.004, Table 2). In the above corre-
lations, patients from all Dukes' stages were included. There were
too few bcl-2(+)/p53(-) patients in Dukes' stage C to allow a sepa-
rate statistical analysis ofthis diagnostic group according to stage.
In multivariate analysis, nodal status was the most important
independent prognostic marker (hazard ratio 1.19, 95% CI
1.07-1.33, P = 0.001), whereas the bcl-2(+)/p53(-) group used
as a variable was not shown to be an independent prognostic
indicator (hazard ratio 0.57, CI 0.13-2.50, P = 0.455).
DISCUSSION
We and others have recently shown that bcl-2, although expressed
in the majority ofcolorectal adenomas, is down-regulated in inva-
sive carcinomas and expressed in approximately 25-50% of the
cases (Watson et al, 1996; Manne et al, 1997; Sneider et al, 1997).
Bcl-2 detection in these neoplasms seems to be correlated with
favourable clinicopathological parameters and better prognosis
(Hague et al, 1994; Ofner et al, 1995; Baretton et al, 1996;
Kaklamanis et al, 1996; Watson et al, 1996; Manne et al, 1997;
Pereira et al, 1997), although the latter has been controversial
(Bosari et al, 1995; Sinicrope et al, 1995; Mosnier et al, 1996).
Recently, it was shown that bcl-2 expression did not influence
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response to chemotherapy for advanced or metastatic disease
(Sneider et al, 1997).
Bcl-2 protein expression in colorectal tumours, as well as in
other types ofsolid neoplasms, is not related to an underlying cyto-
genetic abnormality (14, 18 translocation) (Furihata et al, 1996).
Although the mechanism which controls the accumulation ofbcl-2
protein in tumours is not known, it is likely that post-transcriptional
regulation is responsible for bcl-2 expression (Reed et al, 1987).
Bcl-2 was the first gene to be implicated in the regulation (inhi-
bition) of apoptosis. Accumulating data show that p53 protein is
also associated in the apoptosis pathway acting in opposition to
bcl-2 (Yonish-Rouach et al, 1991). Although the relationship
between these two molecules has not been fully identified, it is
becoming increasingly clear that these two molecules are closely
linked in the regulation of programmed cell death. In a T-cell
lymphoma cell line, apoptosis triggered by wild-type p53 was
inhibited by bcl-2 (Wang et al, 1993). Other reports have shown
that p53 can down-regulate bcl-2 gene expression (Miyashita et al,
1994) and in a breast cell line bcl-2 was down-regulated by over-
expression of a mutant p53 (Halder et al, 1994). In a previous
study (Kaklamanis et al, 1996), carcinomas arising from adenomas
showed loss ofbcl-2 (85% positive adenomas compared with 25%
positive carcinomas), implying that during the adenoma-
carcinoma progression, at the time when p53 mutations usually
take place, bcl-2 expression is down-regulated.
Recently it has been shown that although bcl-2 inhibits apo-
ptosis it also slows down cell growth (Pietenpol et al, 1994). Thus,
if alternative pathways become activated there may be strong
selective pressure to down-regulate bcl-2. In our study, the bcl-
2(+)/p53(-) pathway had the best prognosis and least nodal
involvement, implying that this is a less aggressive neoplastic
transformation pathway, possibly at early stage of development.
The other groups, loss of bcl-2 alone and gain of p53 with or
without bcl-2 loss, had poor prognosis and higher stage. This
suggests progression of the normal phenotype via two pathways,
loss of bcl-2 or gain of expression of abnormal p53 with subse-
quent changes in the other pathway.
Previous studies in other tumour types (Leek et al, 1994) have
shown an inverse correlation ofp53 expression with bcl-2, and our
results are similar. The loss ofbcl-2 associated with a more aggres-
sive phenotype suggests other possible roles for bcl-2, since one
would expect a protein preventing apoptosis to be ofsurvival value
to tumour cells. However, once mutations in p53 occur, this may
no longer be necessary and bcl-2 transfectants have been shown to
slow growth. Thus, bcl-2 loss may allow further progression of a
tumour in the presence of p53 changes or other anti-apoptotic
genes. The association of low stage with the combined bcl-
2(+)/p53(-) phenotype is compatible with the above mechanism.
As shown by others (Hak-Su et al, 1995), p53 expression was
associated with a worse survival, but once adjustment for conven-
tional pathological factors was made no additional predictive value
was obtained. However, both bcl-2 and p53 mutations can confer
drug resistance, and it will be important to assess the combined
role of these genes in survival of patients treated with adjuvant
chemotherapy for Dukes' B and C carcinomas and also in response
to therapy for relapse.
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